Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | ATIC |
| Gene Name: | ATIC |
| Protein Full Name: | Bifunctional purine biosynthesis protein PURH |
| Alias: | AICAR transformylase; AICARFT; Bifunctional purine biosynthesis protein; IMP synthetase; IMPCHASE; Inosinicase; Phosphoribosylaminoimidazolecarboxamide formyltransferase; Phosphoribosylaminoimidazolecarboxamide formyltransferase/IMP cyclohydrolase; PUR9; PURH |
| Mass (Da): | 64616 |
| Number AA: | 592 |
| UniProt ID: | P31939 |
| Locus ID: | 471 |
| COSMIC ID: | ATIC |
| Gene location on chromosome: | 2q35 |
| Cancer protein type: | OP |
| Effect of cancer mutation on protein: | UNCLEAR |
| Effect of active protein on cancer: | PROMOTES |
| Number of cancer specimens: | 20456 |
| Percent of cancer specimens with mutations: | 0.04 |
| Deregulated in translocations: | inv(2)(p23q35): ATIC-ALK |
| Normal role description: | Metabolic enzyme - Purine synthesis. Bifunctional enzyme that catalyzes 2 steps in purine biosynthesis. In the ATIC-ALK fusion protein, ATIC activates the tyrosine kinase ALK constitutively (via autophosphorylation) and thereby promotes oncogensis. |